United States: GSK obtained substantial regulatory approval in the UK. Once approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), two drug combinations containing Blenrep received authorization to treat adults with relapsed or refractory multiple myeloma following their first therapy, as reported by Reuters.
The Combinations: Blenrep + Standard Therapies
The greenlight applies to two specific combinations:
- Blenrep + bortezomib + dexamethasone
- Blenrep + pomalidomide + dexamethasone
Both bortezomib and pomalidomide are well-established cancer treatments paired here with the common steroid dexamethasone.
A Comeback After US Withdrawal
Blenrep experienced a major comeback since its US market removal in 2022 due to failed trials when the FDA approved the drug in June 2023. The drug strengthens its position as a candidate for global oncology care through positive results from recent large-scale clinical evaluations.
#News for #Investors and #Media
— GSK (@GSK) April 17, 2025
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed one of our blood cancer therapies.
More information for media and investors: https://t.co/8z9eFhfDRj pic.twitter.com/uCu7pHY3Q0
How Blenrep Works?
The ADC category consists of products like Blenrep, which is one of its innovative members. This intelligent therapeutic technology connects to cancer cell proteins called BCMA and transports toxic substances into tumors without affecting normal body cells, as reported by Reuters.
Why It Matters?
Multiple myeloma is the third most common blood cancer worldwide. While treatable, it remains incurable. Blenrep offers renewed hope, with the potential to improve survival and remission rates when used after the first relapse.